Neratinib Maleate Tablets

New drug for the extended adjuvant therapy of HER2+breast cancer worldwide

Neratinib Maleate Tablets is an oral irreversible small molecule pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor(TKI) indicated for the extended adjuvant treatment of adult patients with early-stage HER2+breast cancer after adjuvant trastuzumab-based therapy and the treatment of adult patients with metastatic advanced HER2+breast cancer who have received two or more treatment regimens, as recommended by many authoritative guidelines worldwide.

Indications

As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy.

Strength

40mg, 180tablets/bottle